Obsidian Therapeutics, Inc. Common Stock Total Liabilities
Obsidian Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Obsidian Therapeutics, Inc. Common Stock (OBX) has total liabilities worth $346.33 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OBX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Obsidian Therapeutics, Inc. Common Stock (2024–2025)
Total liabilities of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how Obsidian Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Obsidian Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Obsidian Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Svenska Handelsbanken AB (publ)
ST:SHB-B
|
Sweden | Skr3.69 Trillion |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
Sumavision Technologies
SHE:300079
|
China | CN¥431.64 Million |
|
POSCO-Thainox Public Company Limited
BK:INOX
|
Thailand | ฿2.27 Billion |
|
Rigol Technologies Co. Ltd. A
SHG:688337
|
China | CN¥371.38 Million |
|
Dogan Sirketler Grubu Holding AS
IS:DOHOL
|
Turkey | TL108.02 Billion |
|
Develop Global Ltd
AU:DVP
|
Australia | AU$269.24 Million |
|
Macquarie Technology Group Ltd
AU:MAQ
|
Australia | AU$292.18 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Obsidian Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OBX current and non-current assets.
Liquidity & Leverage Metrics
Obsidian Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Obsidian Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Obsidian Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $354.62 Million | -0.98% |
| 2024-12-31 | $358.14 Million | -- |
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more